Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

COVID-19 Therapeutics Accelerator awards $20 million in initial grants to fund clinical trials

Awards and Appointments Coronavirus COVID-19 General

Researchers at Mahidol Oxford Tropical Medicine Research Unit (MORU) and two institutions in the US (University of Washington and La Jolla Institute for Immunology) receive grants from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard to speed the development of and access to therapies for COVID-19.

2019-nCov novel coronavirus microscope close up concept

Today, the partners in the COVID-19 Therapeutics Accelerator announced grants of $20 million to three institutions - the University of Washington, the Mahidol Oxford Tropical Medicine Research Unit (MORU), and La Jolla Institute for Immunology - to fund clinical trials to identify highly potent immunotherapies for the COVID-19 pandemic.

These grants mark the first investments to come from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19. Currently, there are no broad-spectrum antivirals or immunotherapies available to prevent or treat COVID-19. 

Read the full story on the Centre for Tropical Medicine & Global Health website

Similar stories